Elsevier announces standards-ready clinical decision support enhancements in Gold Standard Drug Database to enable interoperability and transparency in healthcare applications

Elsevier announced new clinical decision support (CDS) enhancements in its Gold Standard Drug Database (GSDD) that enable customers to use industry-standard identifiers across core medication safety checks and provide transparent responses when no alert is triggered. The updates aim to help healthcare technology companies and pharmacy organizations integrate CDS faster, reduce manual exception queues, and operate confidently in multi‑vendor ecosystems.

GSDD now accepts RxNorm (RxCUIs) ICD‑10-CM, ICD-10-PCS and SNOMED CT as inputs for drug interaction, duplicate therapy and drug–disease safety checks, including contraindications and precautions. New input validation delivers explicit “reason responses” when no alert is produced, giving product and engineering teams clear, actionable insight into CDS behavior.

Elsevier is also enhancing Drug-Allergy safety checking, made available in March 2026, with support for RxCUI and SNOMED CT allergen inputs. A new allergy catalogue will be introduced to support clinician, patient, and consumer documentation, RxNorm and SNOMED CT drug substances, brands, drug classes, dietary and environmental allergens.

Rhett Alden, Chief Technology Officer at Elsevier said “These standards-ready capabilities reflect our commitment to helping customers meet interoperability requirements while improving operational efficiency. RxNorm, ICD-10, and SNOMED CT are cornerstone clinical terminologies that make interoperability possible by ensuring different systems mean the same thing when they exchange data. By utilizing these industry standard identifiers and providing transparent responses, we’re supporting safer, faster workflows without requiring our valued customers to rearchitect their systems. Transparency matters in clinical decision support – clear responses reduce unnecessary exception reviews and accelerate troubleshooting. Combined with standards-based inputs, customers can implement CDS more quickly and trust the results they see.”

The enhancements reinforce Elsevier’s clinical depth and ongoing content maintenance, aligning with the company’s broader focus on delivering safety, efficiency, and scalability across the health information ecosystem.

About Gold Standard Drug Database

Elsevier’s Gold Standard Drug Database (GSDD) provides normalized, clinically curated medication product and semantic data to help organizations standardize drug information and support medication management, clinical decision support, and interoperability across healthcare workflows. Maintained by clinical pharmacists and subject‑matter experts, GSDD integrates via flexible data feeds and APIs and is used by health systems, payers, pharmacies, and health‑technology companies.

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,300 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundationopens in new tab/window) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELXopens in new tab/window 的一部分，RELXopens in new tab/window 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。